1381782-08-6
Chemical Structure
Viriditoxin
Synonym(s): (-)-Viriditoxin
- CAS No.: 1381782-08-6
- Formula:C34H30O14
- Molecular Weight:662.60
IUPAC Name: dimethyl 2,2'-(9,9',10,10'-tetrahydroxy-7,7'-dimethoxy-1,1'-dioxo-3,3',4,4'-tetrahydro-1H,1'H-[6,6'-bibenzo[g]isochromene]-3,3'-diyl)diacetate
InChIKey: GMCZVCXZGZGZPX-UHFFFAOYSA-N
SMILES: O=C1OC(CC(=O)OC)CC2=CC3=C(C(O)=CC(OC)=C3C4=C(OC)C=C(O)C=5C(O)=C6C(=O)OC(CC(=O)OC)CC6=CC54)C(O)=C12
Biological Activity: Viriditoxin ((-)-Viriditoxin) is a mycotoxin. Viriditoxin promotes tubulin polymerization, and inhibits FtsZ polymerization and GTPase activity. Viriditoxin exhibits cytotoxicity against cancer cells, induces apoptosis, inhibits cell migration and colony formation, induces G2/M phase arrest, and triggers autophagic cell death. Viriditoxin activates caspase-3, cleaves PARP, promotes cytochrome c release, and induces ROS production. Viriditoxin possesses broad-spectrum antibacterial activity against Gram-positive pathogenic bacteria, fish pathogenic bacteria, and permeabilized Gram-negative bacteria. Viriditoxin can be used in research related to ovarian cancer, lung cancer, nasopharyngeal carcinoma, colon cancer, neuroblastoma, prostate cancer, leukemia, lymphoma, bacterial infections, and streptococcosis[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Viriditoxin | Viriditoxin ((-)-Viriditoxin) is a mycotoxin. Viriditoxin promotes tubulin polymerization, and inhibits FtsZ polymerization and GTPase activity. Viriditoxin exhibits cytotoxicity against cancer cells, induces apoptosis, inhibits cell migration and colony formation, induces G2/M phase arrest, and triggers autophagic cell death. Viriditoxin activates caspase-3, cleaves PARP, promotes cytochrome c release, and induces ROS production. Viriditoxin possesses broad-spectrum antibacterial activity against Gram-positive pathogenic bacteria, fish pathogenic bacteria, and permeabilized Gram-negative bacteria. Viriditoxin can be used in research related to ovarian cancer, lung cancer, nasopharyngeal carcinoma, colon cancer, neuroblastoma, prostate cancer, leukemia, lymphoma, bacterial infections, and streptococcosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Su M, et al. Viriditoxin Stabilizes Microtubule Polymers in SK-OV-3 Cells and Exhibits Antimitotic and Antimetastatic Potential. Marine drugs. 2020 Aug 27;18(9):445. [Content Brief]
- [2]. Kundu S, et al. Viriditoxin regulates apoptosis and autophagy via mitotic catastrophe and microtubule formation in human prostate cancer cells. International journal of oncology. 2014 Dec;45(6):2331-40. [Content Brief]
- [3]. Wang J, et al. Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. The Journal of biological chemistry. 2003 Nov 07;278(45):44424-8. [Content Brief]
- [4]. Grove CI, et al. Second-Generation Synthesis of (-)-Viriditoxin. Synthesis. 2012;2012(3):362-371. [Content Brief]
- [5]. Stuhldreier F, et al. The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism. Cell death & disease. 2022 Nov 08;13(11):938. [Content Brief]
- [6]. Noh TH, et al. Antibacterial activities of viriditoxin congeners and synthetic analogues against fish pathogens. Bioorganic & medicinal chemistry letters. 2017 Nov 15;27(22):4970-4974. [Content Brief]
Keywords
